At a glance
- Originator Abbott Laboratories
- Class Antibacterials
- Mechanism of Action Type II DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Bacterial infections
Most Recent Events
- 10 Jul 1998 No-Development-Reported for Bacterial infections in USA (Unknown route)
- 12 Oct 1995 Preclinical development for Bacterial infections in USA (Unknown route)